{"filings":[{"id":973118,"accession_number":"0001193125-26-265867","cik":1691082,"company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","form_type":"8-K","filed_at":"2026-06-10T20:16:40+00:00","items":["5.02","9.01"],"status":"ready","headline":"LB Pharmaceuticals CMO Anna Eramo resigns; will advise through September 15, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anna Eramo, M.D., resigns as CMO effective June 15, 2026; transitions to advisor role through Sept 15, 2026.","Separation agreement includes base salary until June 15, 2027, prorated 2026 bonus, and accelerated vesting of 66,143 options.","Company states departure is unrelated to clinical operations and expects no material impact on clinical milestones.","Search for replacement underway; existing clinical teams will continue to oversee ongoing trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":789468232.9269783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":945356,"accession_number":"0001193125-26-263724","cik":1691082,"company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","form_type":"8-K","filed_at":"2026-06-09T20:05:22+00:00","items":["5.07"],"status":"ready","headline":"LB Pharma shareholders elect three Class I directors, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors elected: Robert A. Lenz (20,059,577 for), Rebecca Luse (18,530,680), Ran Nussbaum (18,748,511).","Broker non-votes of 3,216,636 on each director election.","Ratification of BDO USA as auditor for FY 2026: 23,275,974 for, 5,490 against, 2,753 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":789468232.9269783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40841,"accession_number":"0001193125-26-219529","cik":1691082,"company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","form_type":"8-K","filed_at":"2026-05-12T20:21:01+00:00","items":["2.02","9.01"],"status":"ready","headline":"LB Pharma Q1 net loss $19.1M; cash $365.6M; Phase 3 schizophrenia trial launched","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.1M in Q1 2026 vs $5.3M in Q1 2025; R&D expenses rose $11.2M to $14.6M.","Cash, equivalents, and marketable securities totaled $365.6M as of March 31, 2026; runway into Q2 2029.","Initiated pivotal Phase 3 NOVA-2 trial of LB-102 in acute schizophrenia; topline data H2 2027.","Phase 2 ILLUMINATE-1 trial in bipolar depression started Jan 2026; topline expected Q1 2028.","Completed $100M private placement in Feb 2026; Phase 2 in adjunctive MDD planned early 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":789468232.9269783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107309,"accession_number":"0001193125-26-126223","cik":1691082,"company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LB Pharmaceuticals reports Q4 net loss $11.5M; cash $295.2M; advances LB-102 into Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive Phase 2 (NOVA-1) results for LB-102 in acute schizophrenia met primary endpoint; Phase 3 NOVA-2 initiated March 2026 with data expected H2 2027.","Phase 2 ILLUMINATE-1 trial in bipolar depression started Jan 2026; Phase 2 for adjunctive MDD planned early 2027.","September 2025 IPO raised $327.8M (21.85M shares at $15); February 2026 private placement added $100M.","Cash and investments $295.2M at Dec 31, 2025; with private placement, runway into Q2 2029.","Q4 2025 net loss $11.5M ($5.1M Q4 2024); full-year net loss $25.2M ($63.1M 2024); R&D expenses declined YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":789468232.9269783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107308,"accession_number":"0001193125-26-108474","cik":1691082,"company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Zachary Prensky to retire from LB Pharmaceuticals board at 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Zachary Prensky notified board on March 13, 2026; will not stand for reelection at the 2026 annual meeting.","Prensky remains on board and Nominating & Governance Committee until the meeting concludes.","Decision was not due to any disagreement with the company; he will provide consulting services post-retirement.","Amendment to Transition Agreement allows unvested stock options to continue vesting during the consulting term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":789468232.9269783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107307,"accession_number":"0001193125-26-099419","cik":1691082,"company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"LB Pharmaceuticals appoints Dr. Robert Lenz to Board and promotes Gad Soffer to COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Lenz, M.D., Ph.D., appointed to Board as Class I director; brings over 20 years of neuroscience R&D experience.","Lenz receives $40,000 annual retainer, $5,000 for Nominating Committee, and initial option grant of 20,000 shares.","Gad Soffer promoted from Chief Business Officer to Chief Operating and Business Officer, effective March 4, 2026.","Soffer's annual base salary increased to $505,000 with target bonus of 40% of base salary.","Lenz previously served as EVP R&D at Neumora Therapeutics and SVP Global Development at Amgen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":789468232.9269783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107306,"accession_number":"0001193125-26-038539","cik":1691082,"company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"LB Pharmaceuticals raises $100M in private placement; Phase 2 MDD trial for LB-102 starts early 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$100M from sale of 3.31M shares and 1.42M pre-funded warrants at $21.17/share.","Investors include Balyasny, Caligan, Commodore, Deep Track, Nantahala, Pivotal, Spruce Street, TCGX, Trails Edge.","Net proceeds to fund Phase 2 trial of LB-102 as adjunctive MDD treatment and for working capital.","Phase 2 trial: 380 patients, 50 sites U.S./Europe, randomized 1:1 vs placebo, primary endpoint MADRS-10 at week 6.","Trial to start early 2027; topline results expected first half 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":789468232.9269783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123667,"accession_number":"0001193125-25-279074","cik":1691082,"company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"LB Pharmaceuticals expands office lease at One Penn Plaza, adds 4,634 sq ft","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment adds 4,634 rentable sq ft on 10th floor; lease expires March 31, 2032.","Annual rent: $430,962 first 3 yrs, then $477,302; 150-day rent abatement.","Landlord to deliver expansion by July 1, 2026; delay credit of $1,180.72/day.","Security amount increased to $740,186.66 under amended lease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":789468232.9269783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123666,"accession_number":"0001193125-25-276070","cik":1691082,"company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LB Pharmaceuticals appoints Kaya Pai Panandiker as Chief Commercial Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Nov 10, 2025; Panandiker previously CCO at Neumora Therapeutics.","She led commercial at Cerevel (acquired by AbbVie) and was GM Neuroscience at Lundbeck.","Oversaw launches of REXULTI, TRINTELLIX, and ABILIFY MAINTENA (blockbuster sales).","Will lead commercialization of lead candidate LB-102 for schizophrenia and bipolar depression.","Company intends to grant her an inducement equity award outside its 2025 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":789468232.9269783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123665,"accession_number":"0001193125-25-268154","cik":1691082,"company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LB Pharmaceuticals Reports Q3 2025 Results and Provides Trial Updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $3.6M in Q3 2025 from $14.2M in Q3 2024.","Raised $327.8M in upsized IPO at $15.00 per share in September 2025.","Plans to initiate Phase 3 schizophrenia trial with ~460 patients in Q1 2026, topline expected H2 2027.","Appointed William Kane and Rekha Hemrajani to Board, James Rawls as SVP of Regulatory Affairs.","Cash position of $314.5M expected to fund operations into Q2 2028."],"consensus_eps_estimate":-0.4641,"consensus_eps_actual":-6.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":789468232.9269783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140348,"accession_number":"0001193125-25-202195","cik":1691082,"company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"LB Pharmaceuticals adopts amended charter and bylaws upon IPO closing on Sept 12, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed amended and restated certificate of incorporation with Delaware Secretary of State.","Adopted amended and restated bylaws effective immediately prior to IPO closing.","Both documents previously approved by board and stockholders.","IPO closed on September 12, 2025; common stock trades on Nasdaq under LBRX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":789468232.9269783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}